Published Date: 20-Jan-2023
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Pressotherapy Systems Market size is expected to reach $215.7 Million by 2028, rising at a market growth of 4.5% CAGR during the forecast period.
The Veno-Lymphatic Circulation segment acquired maximum revenue share in the Global Pressotherapy Systems Market by Application in 2021 thereby, achieving a market value of $60 Million by 2028. A system called veno-lymphatic circulation makes it easier for venous blood to go from the legs to the heart and back to the veins. As pressotherapy increases the effectiveness of lymphatic and venous circulation, it forces fluid from the limbs' extremities inside.
The Hospitals segment is showcasing a CAGR of 5.1% during (2022 - 2028). Due to growing public awareness of obesity-related illnesses like heart disease, stroke, type 2 diabetes, and cancer, hospitals are implementing these devices. Furthermore, the market expansion in this sector is fuelled by the rising prevalence of chronic illnesses brought on by obesity.
The North America market dominated the Global Pressotherapy Systems Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $78.8 Million by 2028. The Europe market is exhibiting a CAGR of 4.3% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 5.3% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of DJO Global (Enovis), BardoMed Sp. z o.o (CarePump), HEAT Spa Kur Therapy Development, Inc., Novasonix Technology S.L., Elettronica Pagani SRL, Zhende Medical Co, Ltd, Guangzhou Longest Science & Technology Co., Ltd., and Atrex SRL (Alyssatech).
By End Use
Unique Offerings from KBV Research